ImmunityBio, Inc. (IBRX)

Market Cap	2.46B
Revenue (ttm)	556,000
Net Income (ttm)	-458.02M
Shares Out	667.71M
EPS (ttm)	-1.05
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	4,638,669
Open	4.06
Previous Close	3.98
Day's Range	3.65 - 4.08
52-Week Range	1.21 - 7.10
Beta	-0.61
Analysts	Hold
Price Target	4.00 (+8.7%)
Earnings Date	Nov 9, 2023

About IBRX

ImmunityBio, Inc., a clinical-stage biotechnology company, engages in developing therapies and vaccines that complement, harness, and amplify the immune system to defeat cancers and infectious diseases in the United States and Europe. It offers immunotherapy and cell therapy platforms, including antibody cytokine fusion protein N-803, vaccine technologies, toll-Like receptor activating adjuvants, natural killer cells, and damage-associated molecular patterns inducers. The company also develops therapeutic agents, which are in Phase II or III cl...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2014
• Employees: 725
• Stock Exchange: NASDAQ
• Ticker Symbol: IBRX

Financial Performance

In 2022, ImmunityBio's revenue was $240,000, a decrease of -74.30% compared to the previous year's $934,000. Losses were -$416.57 million, 20.1% more than in 2021.

Analyst Forecast

According to one analyst, the rating for IBRX stock is "Hold" and the 12-month stock price forecast is $4.0.

Price Target

$4.0

(8.70% upside)

Analyst Consensus: Hold